Metabolic syndrome (MS) is associated with an increased risk of more aggressive prostate cancer (PCa), according to researchers in Spain.

In a study of 2,408 men who underwent prostatic biopsies, Juan Morote, MD, of Vall d’Hebron Hospital and Research Institute, and his co-investigators observed no significant difference in the detection rate of PCa overall between men with MS and those without it (34.5% and 36.4%, respectively), according to a online report in BJU International.

They did find, however, that patients with MS had a significantly higher rate of high-grade PCa (Gleason score 8-10) than those without MS (35.9% vs. 23.9%). Multivariate analyses confirmed that MS was not associated with the risk of PCa, but was associated with a significant 75% increased risk of high-grade tumors.

Continue Reading